Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 26/10/2020
SIETES contiene 93135 citas

 
 
 1 a 20 de 89 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Jefferson T, Demasi M, Doshi P. Statins for primary prevention: what is the regulator’s role?. BMJ Evidence-Based Medicine 2020:marzo. [Ref.ID 103575]
2.Enlace a cita originalTiene citas relacionadas Cita con resumen
Newman CB, Preiss D, Tobert JA, Jacobson TA, Page II RL, Goldstein LB, Chin C, Tannock LR, Miller M, Raghuveer G, Duell PB, Brinton EA, Pollak A, Braun LT, Welty FK. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology 2019;39:enero. [Ref.ID 103011]
3.Enlace a cita original Cita con resumen
Bielecka-Dabrowa A, Fabis J, Mikhailidis DP, von Haehling S, Sahebkar A, Rysz J, Banach M. Prosarcopenic effects of statins may limit their effectiveness in patients with heart failure. Trends Pharmacol Sci 2018;39:abril. [Ref.ID 102681]
4. Cita con resumen
Pedro-Botet J, Rubiés-Prat J. Statin-associated muscle symptoms: beware of the nocebo effect. Lancet 2017;389:2445-6. [Ref.ID 101655]
6. Cita con resumen
Anónimo. Fluoroquinolones et troubles musculosquelettiques persistants. Prescrire 2016;36:513. [Ref.ID 100556]
8. Cita con resumen
Galliver M. Media coverage of statins may have led to 2000 cardiovascular events. BMJ 2016;353:i3630. [Ref.ID 100486]
9. Cita con resumen
Ezquerra Pérez G, Martín de la Nava MA, Álvarez-Cienfuegos A, Montaño Barrientos A, Baquero Barroso MJ, Rubio Núñez PL, Gómez Santana MC, Gavilán Moral E, Candela Marroquín E, Sánchez Robles GA. Revisión GRADE de estatinas en población con = 90% en prevención primaria cardiovascular. Sección 3: Efectos adversos. II. Miopatías.. Grupo Evalmed-GRADE 2016:21 de enero. [Ref.ID 99983]
10. Cita con resumen
Anónimo. FDA approves new orphan drug to treat pulmonary arterial hypertension. U.S. Food and Drug Administration 2015:22 de diciembre. [Ref.ID 99740]
11.Tiene citas relacionadas Cita con resumen
Huffman MD. The polypill: from promise to pragmatism. PLOS Medicine 2015;12:11 de agosto. [Ref.ID 99454]
12. Cita con resumen
Anónimo. FDA approves first biosimilar product Zarxio. U.S. Food and Drug Administration 2015:6 de marzo. [Ref.ID 98838]
13.
Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, Roden M, Stein E, Tokgözoglu L, Nordestgaard BG, Bruckert E, De Backer G, Krauss RM, Laufs U, Santos RD, Hegele RA, Hovingh GK, Leiter LA, Mach F, März W, Newman CB, Wiklund O, Jacobson TA, Catapano AL, Chapman MJ, Ginsberg HN. Statin-associated muscle symptoms: impact on statin therapy — European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management (CC) . Eur Heart J 2015;36:1012-22. [Ref.ID 98806]
14. Cita con resumen
Taylor BA, Lorson L, White CM, Thompson PD. A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy. Atherosclerosis 2015;238:329-35. [Ref.ID 98738]
15. Cita con resumen
Turner JP, Shakib S, Singhal N, Hogan-Doran J, Prowse R, John S, Thynne T, Bell JS. Statin use and pain in older people with cancer: a cross-sectional study. J Am Geriatr Soc 2014;62:1900-5. [Ref.ID 98397]
16. Cita con resumen
Godlee F. Statins and The BMJ. BMJ 2014;349:g5038. [Ref.ID 98177]
17.Enlace a cita original Cita con resumen
Desai CS, Martin SS, Blumenthal RS. Non-cardiovascular effects associated with statins. BMJ 2014;349:g3743. [Ref.ID 98147]
18.
Prasad V. Statins, primary prevention, and overall mortality. Ann Intern Med 2014;160:867-9. [Ref.ID 97767]
19. Cita con resumen
20.Tiene citas relacionadas Cita con resumen
Golomb BA. Statins and activity. Proceed with caution. JAMA Intern Med 2014;174:1270-2. [Ref.ID 97622]
Seleccionar todas
 
 1 a 20 de 89 siguiente >>